developed by Eli Lilly and Company, retatrutide has shown exceptional results in clinical research, with phase 2 trials demonstrating average weight loss of up to 24% over 48 weeks alongside improvements in insulin sensitivity, blood glucose regulation, lipid profiles, and reductions in visceral fat and liver fat, positioning it as one of the most promising next-generation obesity treatments currently under study
Peptides are involved in many different processes in your body, so potential side effects depend on the peptide you are taking and how you're taking it
In BECs, PICALM guides A trafficking to Rab5-positive early endosomes and Rab11 that leads to A transcytosis rather than Rab7, a GTPase that directs to lysosomes leading to degradation of ligands (Zhao et al., 2015b)
UCSF ChimeraX: structure visualization for researchers, educators, and developers
[PMID: 13130552] PubMed record related to this compound for laboratory literature review